Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colore...
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
About this item
Full title
Author / Creator
Macarulla, T , Cervantes, A , Tabernero, J , Roselló, S , Van Cutsem, E , Tejpar, S , Prenen, H , Martinelli, E , Troiani, T , Laffranchi, B , Jego, V , von Richter, O and Ciardiello, F
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background:
The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib.
Methods:
Patients with
KRAS
mutant mCRC were treated in the second...
Alternative Titles
Full title
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4580393
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4580393
Other Identifiers
ISSN
0007-0920
E-ISSN
1532-1827
DOI
10.1038/bjc.2015.144
